{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:25:54Z","timestamp":1790774754842,"version":"4.1.0"},"reference-count":234,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacc.2026.01.024","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:04:29Z","timestamp":1773237869000},"page":"454-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pulmonary Hypertension Associated With Left Heart Disease"],"prefix":"10.1016","volume":"88","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N.V.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Tedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.01.024_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.819145","article-title":"Dysregulated immunity in pulmonary hypertension: from companion to composer","volume":"13","author":"Funk-Hilsdorf","year":"2022","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"38","key":"10.1016\/j.jacc.2026.01.024_bib3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachi\u00e9ry","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02427-2017","article-title":"Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis","volume":"51","author":"Caravita","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14017431.2017.1311023","article-title":"Prevalence of heart failure in the elderly and future projections: the AGES-Reykjav\u00edk study","volume":"51","author":"Danielsen","year":"2017","journal-title":"Scand Cardiovasc J"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib7","article-title":"Increasing incidence and prevalence of world health organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada","volume":"11","author":"Thiwanka Wijeratne","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib8","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1164\/rccm.201503-0529OC","article-title":"Pulmonary hypertension in heart failure epidemiology, right ventricular function, and survival","volume":"192","author":"Gerges","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"10.1016\/j.jacc.2026.01.024_bib9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction. a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jacc.2026.01.024_bib10","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs clinical assessment, reporting, and tracking program","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","article-title":"Mild elevation of pulmonary arterial pressure as a predictor of mortality","volume":"197","author":"Douschan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.chest.2022.09.040","article-title":"Evidence of advanced pulmonary vascular remodeling in obstructive hypertrophic cardiomyopathy with pulmonary hypertension","volume":"163","author":"Maron","year":"2023","journal-title":"Chest"},{"issue":"21","key":"10.1016\/j.jacc.2026.01.024_bib13","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jacc.2019.03.482","article-title":"Threshold of pulmonary hypertension associated with increased mortality","volume":"73","author":"Strange","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jacc.2026.01.024_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009729","article-title":"Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis","volume":"7","author":"Kolte","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.jacc.2026.01.024_bib15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"44","key":"10.1016\/j.jacc.2026.01.024_bib17","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1093\/eurheartj\/ehad532","article-title":"Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC\/ERS guidelines: the EVIDENCE-PAH UK study","volume":"44","author":"Karia","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.01.024_bib18","doi-asserted-by":"crossref","unstructured":"G\u00fcder G, Reiter T, Fette G, et al. Diagnosing post-capillary hypertension in patients with left heart disease: impact of new guidelines. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-023-02290-5","DOI":"10.1007\/s00392-023-02290-5"},{"issue":"11","key":"10.1016\/j.jacc.2026.01.024_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/clc.22579","article-title":"Combined post- and precapillary pulmonary hypertension in patients with heart failure","volume":"39","author":"Rezaee","year":"2016","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/688516","article-title":"Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension","volume":"6","author":"Assad","year":"2016","journal-title":"Pulm Circ"},{"issue":"36","key":"10.1016\/j.jacc.2026.01.024_bib21","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchf.2014.07.010","article-title":"The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease","volume":"3","author":"Tampakakis","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018815438","article-title":"Hemodynamics of the diastolic pressure gradients in acute heart failure: implications for the diagnosis of pre-capillary pulmonary hypertension in left heart disease","volume":"9","author":"Aronson","year":"2019","journal-title":"Pulm Circ"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004436","article-title":"Pulmonary effective arterial elastance as a measure of right ventricular afterload and its prognostic value in pulmonary hypertension due to left heart disease","volume":"11","author":"Tampakakis","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1164\/rccm.202402-0359VP","article-title":"\u201cThis patient needs a doctor, not a guideline!\u201d The zone of uncertainty in pulmonary arterial wedge pressure measurement","volume":"210","author":"Rayner","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1016\/j.jacc.2026.01.024_bib27","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib28","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ejhf.1699","article-title":"Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction","volume":"22","author":"Tamargo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.024_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fmed.2018.00174","article-title":"Pathophysiology and diagnosis of pulmonary hypertension due to left heart disease","volume":"5","author":"Charalampopoulos","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.CIR.69.2.214","article-title":"Pulmonary arterial V waves in mitral regurgitation: clinical and experimental observations","volume":"69","author":"Grose","year":"1984","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1056\/NEJMoa021650","article-title":"Signaling molecules in nonfamilial pulmonary hypertension","volume":"348","author":"Du","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/HYPERTENSIONAHA.117.08824","article-title":"Models and molecular mechanisms of world health organization group 2 to 4 pulmonary hypertension","volume":"71","author":"Xiong","year":"2018","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217745019","article-title":"The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension","volume":"8","author":"Meoli","year":"2018","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCHEARTFAILURE.113.000823","article-title":"Pulmonary hypertension in heart failure preserved ejection fraction prevalence, pathophysiology, and clinical perspectives","volume":"7","author":"Guazzi","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"25 suppl","key":"10.1016\/j.jacc.2026.01.024_bib37","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1465-9921-10-95","article-title":"Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation","volume":"10","author":"Sakao","year":"2009","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/hh2401.100844","article-title":"Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant","volume":"89","author":"Sartore","year":"2001","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/2045893218757596","article-title":"Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series)","volume":"8","author":"Kuebler","year":"2018","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib41","doi-asserted-by":"crossref","first-page":"H1498","DOI":"10.1152\/ajpheart.00068.2024","article-title":"Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction","volume":"326","author":"Aradhyula","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.013208","article-title":"Transpulmonary proteome gradients identify pathways involved in pulmonary vascular disease due to heart failure","volume":"18","author":"Melenovsky","year":"2025","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib43","doi-asserted-by":"crossref","first-page":"L710","DOI":"10.1152\/ajplung.00311.2016","article-title":"The mast cell\u2013B cell axis in lung vascular remodeling and pulmonary hypertension","volume":"312","author":"Breitling","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib44","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1164\/rccm.202501-0034OC","article-title":"Metabolomic evidence of biological overlap with heart failure with preserved ejection fraction in a subset of pulmonary arterial hypertension","volume":"211","author":"Reddy","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib45","doi-asserted-by":"crossref","DOI":"10.31083\/RCM25781","article-title":"Dysregulation of mitochondrial in pulmonary hypertension-related right ventricular remodeling: pathophysiological features and targeting drugs","volume":"26","author":"Wang","year":"2025","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.hlc.2017.09.015","article-title":"Left heart disease and pulmonary hypertension: are we seeing the full picture?","volume":"27","author":"Chung","year":"2018","journal-title":"Heart Lung Circ"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib47","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib48","first-page":"816","article-title":"The complex relationship that is RV-PA coupling and its relevance to managing congenital heart disease","volume":"35","author":"Sathananthan","year":"2019","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/echo.12309","article-title":"Global and regional right ventricular dysfunction in pulmonary hypertension","volume":"31","author":"Calcutteea","year":"2014","journal-title":"Echocardiography"},{"issue":"45","key":"10.1016\/j.jacc.2026.01.024_bib50","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.jacc.2026.01.024_bib51","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.121.054858","article-title":"Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction","volume":"144","author":"Burrage","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jmri.29044","article-title":"Biventricular dysfunction and ventricular interdependence in patients with pulmonary hypertension: a 3.0-T cardiac MRI feature tracking study","volume":"60","author":"Fang","year":"2024","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib53","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11596-020-2198-9","article-title":"Vascular metabolic mechanisms of pulmonary hypertension","volume":"40","author":"Shi","year":"2020","journal-title":"Curr Med Sci"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128220","article-title":"Pressure overload leads to coronary plaque formation, progression, and myocardial events in ApoE\u2212\/\u2212 mice","volume":"4","author":"Marino","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib56","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ajpath.2011.06.037","article-title":"Paigen diet-fed apolipoprotein e knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner","volume":"179","author":"Lawrie","year":"2011","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.jacc.2026.01.024_bib57","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2025.03.530","article-title":"Disentangling the impact of adiposity from insulin resistance in heart failure with preserved ejection fraction","volume":"85","author":"Reddy","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib58","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.115.018935","article-title":"SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"133","author":"Lai","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1165\/rcmb.2016-0177OC","article-title":"Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction","volume":"56","author":"Meng","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurjhf\/hfp171","article-title":"Caveat medicus! Pulmonary hypertension in the elderly: a word of caution","volume":"12","author":"Boilson","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2026.01.024_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100822","article-title":"Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension","volume":"34","author":"Gall","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"171","key":"10.1016\/j.jacc.2026.01.024_bib63","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0144-2023","article-title":"Clinical\u2013imaging\u2013pathological correlation in pulmonary hypertension associated with left heart disease","volume":"33","author":"van de Veerdonk","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib64","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1016\/j.ijcard.2013.07.005","article-title":"Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension","volume":"168","author":"D\u2019Alto","year":"2013","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib65","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1378\/chest.10-1269","article-title":"Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice","volume":"139","author":"Rich","year":"2011","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib66","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1164\/rccm.200811-1691OC","article-title":"Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension","volume":"179","author":"Fisher","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib67","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001103","article-title":"Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: Analysis in a large patient population","volume":"3","author":"Greiner","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib68","doi-asserted-by":"crossref","first-page":"G11","DOI":"10.1530\/ERP-17-0071","article-title":"Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography","volume":"5","author":"Augustine","year":"2018","journal-title":"Echo Res Pract"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib69","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.chest.2022.12.045","article-title":"Derivation of a risk score (REVEAL-ECHO) based on echocardiographic parameters of patients with pulmonary arterial hypertension","volume":"163","author":"El-Kersh","year":"2023","journal-title":"Chest"},{"issue":"40","key":"10.1016\/j.jacc.2026.01.024_bib70","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib71","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04625-2020","article-title":"Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype","volume":"58","author":"Oldham","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.11-1387","article-title":"Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL registry","volume":"143","author":"Frost","year":"2013","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib73","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","article-title":"The role of the pericardium in heart failure: implications for pathophysiology and treatment","volume":"7","author":"Borlaug","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"40","key":"10.1016\/j.jacc.2026.01.024_bib74","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1093\/eurheartj\/ehaf392","article-title":"Pulmonary arterial wedge pressure exceeding left atrial pressure: clinical implications","volume":"46","author":"Tada","year":"2025","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.jacc.2026.01.024_bib75","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.jacc.2024.08.061","article-title":"Clinical implications of pretest probability of HFpEF on outcomes in precapillary pulmonary hypertension","volume":"84","author":"Reddy","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002023","article-title":"Predicting group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland","volume":"9","author":"Stubbs","year":"2022","journal-title":"Open Heart"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib77","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","article-title":"An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score","volume":"30","author":"Reddy","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.chest.2016.08.1439","article-title":"Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension","volume":"151","author":"D\u2019Alto","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018819803","article-title":"Clinical and hemodynamic factors in predicting response to fluid challenge during right heart catheterization","volume":"9","author":"Moghaddam","year":"2019","journal-title":"Pulm Circ"},{"issue":"22","key":"10.1016\/j.jacc.2026.01.024_bib80","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016339","article-title":"Normal and abnormal relationships of pulmonary artery to wedge pressure during exercise","volume":"9","author":"Bentley","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12103","article-title":"The role of exercise right heart catheterization to guide pulmonary hypertension therapy in older adults","volume":"12","author":"Mak","year":"2022","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201402-0269PP","article-title":"Reading pulmonary vascular pressure tracings: how to handle the problems of zero leveling and respiratory swings","volume":"190","author":"Kovacs","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib83","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.hfc.2018.03.011","article-title":"Right heart catheterization for the diagnosis of pulmonary hypertension: controversies and practical issues","volume":"14","author":"D\u2019Alto","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21693\/1933-088X-10.1.33","article-title":"The nuts and bolts of interpreting hemodynamics in pulmonary hypertension associated with diastolic heart failure","volume":"10","author":"Mathier","year":"2011","journal-title":"Adv Pulm Hypertens"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib85","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1378\/chest.12-2114","article-title":"WHO\u2019s in second? A practical review of World Health Organization group 2 pulmonary hypertension","volume":"144","author":"Hansdottir","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib86","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00880-2025","article-title":"Attenuated benefit to vasodilators in patients with pulmonary arterial hypertension and high probability of heart failure with preserved ejection fraction","volume":"66","author":"Reddy","year":"2025","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019841990","article-title":"Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)","volume":"9","author":"Kiely","year":"2019","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCIMAGING.108.780247","article-title":"Magnetic resonance-derived 3-dimensional blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure","volume":"1","author":"Reiter","year":"2008","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.01.024_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.972142","article-title":"Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension","volume":"9","author":"Reiter","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jmri.23844","article-title":"Hyperpolarized 129Xe MRI of the human lung","volume":"37","author":"Mugler","year":"2013","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1152\/japplphysiol.00326.2014","article-title":"Measuring diffusion limitation with a perfusion-limited gas-hyperpolarized 129Xe gas-transfer spectroscopy in patients with idiopathic pulmonary fibrosis","volume":"117","author":"Kaushik","year":"2014","journal-title":"J Appl Physiol"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib92","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01651-2024","article-title":"Xenon-129 magnetic resonance imaging and spectroscopy detects response to therapy in pulmonary hypertension","volume":"65","author":"Alenezi","year":"2025","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib93","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/17476348.2025.2529543","article-title":"The emerging role of hyperpolarized 129Xe MRI in pulmonary hypertension","volume":"19","author":"Alenezi","year":"2025","journal-title":"Expert Rev Respir Med"},{"issue":"15","key":"10.1016\/j.jacc.2026.01.024_bib94","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.120.051542","article-title":"Exercise stress real-time cardiac magnetic resonance imaging for noninvasive characterization of heart failure with preserved ejection fraction: the HFpEF-Stress trial","volume":"143","author":"Backhaus","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.024_bib95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2018.08.084","article-title":"Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018","volume":"272S","author":"Leuchte","year":"2018","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib96","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jchf.2015.12.016","article-title":"Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction","volume":"4","author":"Hoeper","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"14","key":"10.1016\/j.jacc.2026.01.024_bib97","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","article-title":"Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting","volume":"151","author":"Reddy","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib98","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ejhf.2377","article-title":"Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity","volume":"24","author":"Obokata","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.024_bib99","article-title":"Current understanding of circulating biomarkers in pulmonary hypertension due to left heart disease","volume":"7","author":"Todd","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"3-4","key":"10.1016\/j.jacc.2026.01.024_bib100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000501100","article-title":"Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension","volume":"143","author":"Chowdhury","year":"2019","journal-title":"Cardiology"},{"issue":"45","key":"10.1016\/j.jacc.2026.01.024_bib101","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/eurheartj\/ehz626","article-title":"The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib102","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.amjcard.2019.05.056","article-title":"Relation of lymphangiogenic factor vascular endothelial growth factor-D to elevated pulmonary artery wedge pressure","volume":"124","author":"Houston","year":"2019","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib103","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/ijms17040502","article-title":"MicroRNA and heart failure","volume":"17","author":"Wong","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib104","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1159\/000475569","article-title":"The circulating MicroRNA-206 level predicts the severity of pulmonary hypertension in patients with left heart diseases","volume":"41","author":"Jin","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201836","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction","volume":"13","author":"DuBrock","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib106","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01344-2024","article-title":"Pulmonary hypertension associated with left heart disease","volume":"64","author":"Maron","year":"2024","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib107","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib108","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"20","key":"10.1016\/j.jacc.2026.01.024_bib109","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib111","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib112","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib113","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial","volume":"24","author":"Cooper","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib114","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12872-020-01671-2","article-title":"Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- And postcapillary pulmonary hypertension: a randomized open-label pilot study","volume":"20","author":"Belyavskiy","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"38","key":"10.1016\/j.jacc.2026.01.024_bib115","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.jacc.2026.01.024_bib116","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib117","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/CIRCULATIONAHA.124.069340","article-title":"Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study","volume":"150","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib118","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib119","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib120","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"issue":"15","key":"10.1016\/j.jacc.2026.01.024_bib121","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2015.07.067","article-title":"Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction","volume":"66","author":"Borlaug","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib122","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCRESAHA.116.309184","article-title":"Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction","volume":"119","author":"Borlaug","year":"2016","journal-title":"Circ Res"},{"issue":"18","key":"10.1016\/j.jacc.2026.01.024_bib123","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89620","article-title":"Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"1","author":"Simon","year":"2016","journal-title":"JCI Insight"},{"issue":"17","key":"10.1016\/j.jacc.2026.01.024_bib124","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2018.14852","article-title":"Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial","volume":"320","author":"Borlaug","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib126","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12872-020-01759-9","article-title":"Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib127","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","article-title":"The \u03b2-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction: a randomized controlled trial","volume":"124","author":"Reddy","year":"2019","journal-title":"Circ Res"},{"issue":"16","key":"10.1016\/j.jacc.2026.01.024_bib128","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib129","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cardfail.2019.07.547","article-title":"Hemodynamic effects of pulmonary arterial hypertension-specific therapy in patients with heart failure with preserved ejection fraction and with combined post- and precapillary pulmonary hypertension","volume":"26","author":"Huis in\u2019t Veld","year":"2020","journal-title":"J Card Fail"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib130","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2207410","article-title":"Right ventricular failure","volume":"388","author":"Houston","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib131","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","article-title":"Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study","volume":"12","author":"Zhang","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"10.1016\/j.jacc.2026.01.024_bib132","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib133","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.202211-2097OC","article-title":"Elevated pulmonary arterial compliance is associated with survival in pulmonary hypertension: results from a novel network medicine analysis","volume":"208","author":"Wang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib134","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024449","article-title":"Effect of sacubitril\/valsartan on the right ventricular function and pulmonary hypertension in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of observational studies","volume":"11","author":"Zhang","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib135","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006696","article-title":"Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation","volume":"13","author":"Zern","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.024_bib136","article-title":"The emerging role of sacubitril\/valsartan in pulmonary hypertension with heart failure","volume":"10","author":"Xu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.01.024_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.734697","article-title":"Reduction of pulmonary hypertension after transition to sacubitril\/valsartan in patients with heart failure with preserved ejection fraction","volume":"8","author":"Burgdorf","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib138","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.13952","article-title":"Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"9","author":"Codina","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib139","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1177\/02676591221127924","article-title":"A study of the efficacy of sacubitril\/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease","volume":"38","author":"Ge","year":"2023","journal-title":"Perfusion"},{"issue":"17","key":"10.1016\/j.jacc.2026.01.024_bib140","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib141","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib142","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular\u2013pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib143","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib144","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid receptor antagonism by finerenone attenuates established pulmonary hypertension in rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension"},{"issue":"20","key":"10.1016\/j.jacc.2026.01.024_bib145","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacc.2026.01.024_bib146","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74912-1","article-title":"GLP-1 receptor agonist ameliorates experimental lung fibrosis","volume":"10","author":"Fandi\u00f1o","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2026.01.024_bib148","article-title":"GLP-1 receptor agonists and pulmonary hypertension in diabetes: a promising therapeutic strategy","volume":"55","author":"Albulushi","year":"2025","journal-title":"Am Heart J Plus"},{"issue":"17","key":"10.1016\/j.jacc.2026.01.024_bib149","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.healun.2014.04.014","article-title":"Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor","volume":"34","author":"Benza","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib151","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ejhf.2656","article-title":"Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study","volume":"24","author":"Assmus","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib152","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.hlc.2018.04.299","article-title":"Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure","volume":"28","author":"Selim","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib153","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ehf2.12284","article-title":"Comparison of continuous-flow ventricular assist device therapy with intensive medical therapy in fixed pulmonary hypertension secondary to advanced left heart failure","volume":"5","author":"Kumarasinghe","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"23","key":"10.1016\/j.jacc.2026.01.024_bib154","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/eurheartj\/ehaa696","article-title":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: Results from a large European multicentre randomized controlled trial","volume":"42","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehv337","article-title":"Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial","volume":"37","author":"Ehlken","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib156","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13063-023-07297-x","article-title":"Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial","volume":"24","author":"Palevi\u010di\u016bt\u0117","year":"2023","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib157","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib158","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ejhf.1692","article-title":"Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.jacc.2026.01.024_bib159","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/bph.16055","article-title":"Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure","volume":"180","author":"Verdino","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"24","key":"10.1016\/j.jacc.2026.01.024_bib160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013465","article-title":"Human relaxin-2 fusion protein treatment prevents and reverses isoproterenol-induced hypertrophy and fibrosis in mouse heart","volume":"8","author":"Sun","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib161","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1021\/acs.molpharmaceut.4c00368","article-title":"Engineering and characterization of a long-half-life relaxin receptor RXFP1 agonist","volume":"21","author":"Erlandson","year":"2024","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.jacc.2026.01.024_bib162","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1038\/s41591-025-03939-6","article-title":"Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib163","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.jacc.2026.01.024_bib165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034067","article-title":"Novel relaxin receptor RXFP1 agonist AZD3427 in the treatment of heart failure: a phase 1A\/B, first-in-human, randomized, single-blind, placebo-controlled study","volume":"13","author":"Connolly","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib166","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1002\/ehf2.13669","article-title":"Levosimendan-induced venodilation is mediated by opening of potassium channels","volume":"8","author":"Burkhoff","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib167","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1161\/CIR.0000000000001079","article-title":"Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action: a science advisory from the American Heart Association","volume":"146","author":"Brittain","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib168","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000000859","article-title":"Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use","volume":"76","author":"Papp","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib169","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00059-008-3051-2","article-title":"Safety and effectiveness of levosimendan in patients with predominant right heart failure","volume":"33","author":"Poelzl","year":"2008","journal-title":"Herz"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib170","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/crj.12699","article-title":"Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension","volume":"12","author":"Jiang","year":"2018","journal-title":"Clin Respir J"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib171","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","article-title":"Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial","volume":"9","author":"Burkhoff","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.024_bib172","doi-asserted-by":"crossref","unstructured":"Yaku H, Burkhoff D, Borlaug BA, et al. Oral levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction: rationale and design of the LEVEL trial. J Card Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2025.06.009.","DOI":"10.1016\/j.cardfail.2025.06.009"},{"issue":"suppl_2","key":"10.1016\/j.jacc.2026.01.024_bib173","article-title":"HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction","volume":"44","author":"Schang","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib174","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cardfail.2024.10.027","article-title":"Phase IB study of HS135, a novel activin and GDF inhibitor, in patients with obesity-related heart failure with preserved ejection fraction and pulmonary hypertension leveraging remote pulmonary artery pressure monitoring technology","volume":"31","author":"Sauer","year":"2025","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2008.03.006","article-title":"Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts\u2014role of late sodium current and intracellular ion accumulation","volume":"45","author":"Sossalla","year":"2008","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2026.01.024_bib176","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.healun.2016.07.015","article-title":"Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: a pilot study","volume":"35","author":"Finch","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib177","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCHEARTFAILURE.114.002114","article-title":"Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction","volume":"8","author":"Andersen","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib178","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009120","article-title":"Hemodynamic effects of cyclic guanosine monophosphate-dependent signaling through \u03b23 adrenoceptor stimulation in patients with advanced heart failure: a randomized invasive clinical trial","volume":"15","author":"Bundgaard","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib179","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.2745","article-title":"\u03b23 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial","volume":"25","author":"Garc\u00eda-\u00c1lvarez","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/0975-3583.74258","article-title":"The role of RhoA\/Rho kinase pathway in endothelial dysfunction","volume":"1","author":"Yao","year":"2010","journal-title":"J Cardiovasc Dis Res"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib181","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ppul.21323","article-title":"Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil","volume":"46","author":"Dai","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jacc.2026.01.024_bib182","article-title":"Effects of fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction: a prospective intervention study","volume":"2018","author":"Zhang","year":"2018","journal-title":"Can Respir J"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib183","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944717711379","article-title":"Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds","volume":"11","author":"Rochlani","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib184","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1378\/chest.08-2008","article-title":"Association of the metabolic syndrome with pulmonary venous hypertension","volume":"136","author":"Robbins","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib185","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/crj.12406","article-title":"Prevalence of metabolic syndrome in patients with pulmonary hypertension","volume":"11","author":"Ussavarungsi","year":"2017","journal-title":"Clin Respir J"},{"issue":"25","key":"10.1016\/j.jacc.2026.01.024_bib186","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1161\/CIRCULATIONAHA.124.069479","article-title":"Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction","volume":"149","author":"Naser","year":"2024","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib188","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12471-016-0902-y","article-title":"Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation","volume":"24","author":"Verschure","year":"2016","journal-title":"Neth Heart J"},{"issue":"11","key":"10.1016\/j.jacc.2026.01.024_bib189","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002837","article-title":"Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 Study","volume":"8","author":"Chen","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"8 Pt 2","key":"10.1016\/j.jacc.2026.01.024_bib190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jchf.2023.05.016","article-title":"3-Year outcome in patients with combined precapillary and postcapillary pulmonary hypertension: results from PADN-5 trial","volume":"11","author":"Zhang","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.024_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133078","article-title":"Pulmonary artery denervation in pulmonary hypertension: a comprehensive meta-analysis","volume":"427","author":"Abouzid","year":"2025","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib192","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jchf.2015.01.013","article-title":"Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction","volume":"3","author":"Al-Naamani","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib193","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70131","article-title":"Development of a novel, pulmonary endovascular device to treat patients with pulmonary hypertension","volume":"15","author":"Vollmers","year":"2025","journal-title":"Pulm Circ"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib194","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM196509022731001","article-title":"Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension","volume":"273","author":"Braunwald","year":"1965","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/01.CIR.38.2.261","article-title":"Hemodynamic studies before and after instrumental mitral commissurotomy","volume":"38","author":"Feigenbaum","year":"1968","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacc.2026.01.024_bib196","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM196708242770801","article-title":"Early reduction of pulmonary vascular resistance after mitral-valve replacement","volume":"277","author":"Dalen","year":"1967","journal-title":"N Engl J Med"},{"issue":"6 Pt B","key":"10.1016\/j.jacc.2026.01.024_bib197","article-title":"Atrial shunt therapy for heart failure: an update","volume":"2","author":"Jagadeesan","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"21","key":"10.1016\/j.jacc.2026.01.024_bib198","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/j.jacc.2019.08.1062","article-title":"Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction","volume":"74","author":"Obokata","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacc.2026.01.024_bib199","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/eurheartj\/ehx045","article-title":"Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease","volume":"38","author":"Reddy","year":"2017","journal-title":"Eur Heart J"},{"issue":"10330","key":"10.1016\/j.jacc.2026.01.024_bib200","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jacc.2026.01.024_bib201","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.122.059486","article-title":"Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure","volume":"145","author":"Borlaug","year":"2022","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jacc.2026.01.024_bib202","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.jcin.2018.07.001","article-title":"Interatrial shunting for heart failure: early and late results from the first-in-human experience with the V-Wave system","volume":"11","author":"Rod\u00e9s-Cabau","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"10.1016\/j.jacc.2026.01.024_bib203","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.124.070870","article-title":"Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial","volume":"150","author":"Stone","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2026.01.024_bib204","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcin.2023.03.012","article-title":"Left atrial to coronary sinus shunting for treatment of symptomatic heart failure","volume":"16","author":"Hibbert","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ejhf.3236","article-title":"A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function","volume":"26","author":"Ameri","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"10.1016\/j.jacc.2026.01.024_bib206","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib207","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/clc.22468","article-title":"Correlation of the New York Heart Association classification and the 6-minute walk distance: a systematic review","volume":"38","author":"Yap","year":"2015","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib208","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1179\/2042618612Y.0000000001","article-title":"Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)","volume":"20","author":"Wright","year":"2012","journal-title":"J Man Manip Ther"},{"key":"10.1016\/j.jacc.2026.01.024_bib209","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2474-7-82","article-title":"Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients","volume":"7","author":"Lauridsen","year":"2006","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib210","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1164\/rccm.201209-1596OC","article-title":"Six-minute-walk test in chronic obstructive pulmonary disease: Minimal clinically important difference for death or hospitalization","volume":"187","author":"Polkey","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib211","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib212","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01823246-201223030-00002","article-title":"Triangulating clinically meaningful change in the six-minute walk test in individuals with chronic heart failure: a systematic review","volume":"23","author":"Shoemaker","year":"2012","journal-title":"Cardiopulm Phys Ther J"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib213","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01823246-201324030-00004","article-title":"Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure","volume":"24","author":"Shoemaker","year":"2013","journal-title":"Cardiopulm Phys Ther J"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib214","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02225-2022","article-title":"Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension","volume":"62","author":"Alabed","year":"2023","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib215","doi-asserted-by":"crossref","DOI":"10.1177\/2045894021995055","article-title":"A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension","volume":"11","author":"Bunclark","year":"2021","journal-title":"Pulm Circ"},{"issue":"9","key":"10.1016\/j.jacc.2026.01.024_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102587","article-title":"Minimally important Kansas City Cardiomyopathy Questionnaire changes across the spectrum of heart failure severity","volume":"13","author":"Spertus","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.jacc.2026.01.024_bib217","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020962960","article-title":"Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension","volume":"10","author":"Sitbon","year":"2020","journal-title":"Pulm Circ"},{"issue":"12","key":"10.1016\/j.jacc.2026.01.024_bib218","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1164\/rccm.201701-0150WS","article-title":"Enhancing insights into pulmonary vascular disease through a precision medicine approach: a joint NHLBI-Cardiovascular Medical Research and Education Fund workshop report","volume":"195","author":"Newman","year":"2017","journal-title":"Am J Respir Crit Car Med"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib219","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2022.05.038","article-title":"Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease","volume":"80","author":"Hemnes","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib220","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/ejhf.3302","article-title":"Pulmonary hypertension across the spectrum of left heart and lung disease","volume":"26","author":"Borlaug","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.jacc.2026.01.024_bib221","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.jacc.2022.02.050","article-title":"Venous tone and stressed blood volume in heart failure: JACC review topic of the week","volume":"79","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib222","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCRESAHA.117.311737","article-title":"A multi-center study to improve understanding of pulmonary vascular disease through phenomics","volume":"121","author":"Hemnes","year":"2017","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib223","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jacc.2015.10.072","article-title":"Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension","volume":"67","author":"Lewis","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib224","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ejhf.2254","article-title":"Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction","volume":"23","author":"Sorimachi","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2026.01.024_bib225","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacc.2026.01.024_bib226","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jacc.2011.11.012","article-title":"Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: Longitudinal data from the heart and soul study","volume":"59","author":"Welles","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib227","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11886-018-1027-2","article-title":"Update on devices for diastolic dysfunction: options for a no option condition?","volume":"20","author":"Gupta","year":"2018","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib228","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacc.2026.01.024_bib229","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0735-1097(98)00437-9","article-title":"Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure","volume":"32","author":"H\u00fclsmann","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib230","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011381","article-title":"Macitentan for heart failure with preserved or mildly reduced ejection fraction and pulmonary vascular disease: results of the SERENADE randomized clinical trial and open-label extension study","volume":"18","author":"Shah","year":"2025","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.jacc.2026.01.024_bib231","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","article-title":"Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial)","volume":"26","author":"Koller","year":"2017","journal-title":"Heart Lung Circ"},{"issue":"2","key":"10.1016\/j.jacc.2026.01.024_bib232","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019949","article-title":"Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival","volume":"10","author":"Bermejo","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacc.2026.01.024_bib233","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12034","article-title":"The comparative effects of sacubitril\/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction","volume":"12","author":"Zhao","year":"2022","journal-title":"Pulm Circ"},{"issue":"10025","key":"10.1016\/j.jacc.2026.01.024_bib234","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0140-6736(16)00704-2","article-title":"A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial","volume":"387","author":"Hasenfu\u00df","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacc.2026.01.024_bib235","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"8 Pt 2","key":"10.1016\/j.jacc.2026.01.024_bib236","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jchf.2023.01.024","article-title":"No-implant interatrial shunt for HFpEF: 6-month outcomes from multicenter pilot feasibility studies","volume":"11","author":"Udelson","year":"2023","journal-title":"JACC Heart Fail"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726001348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726001348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:35:16Z","timestamp":1785965716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":234,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0735109726001348"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.01.024","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Hypertension Associated With Left Heart Disease","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}